PLASMA S100P & HYALURONIC ACID LEVEL AS PROGNOSTIC & TREATMENT MONITORING MARKERS FOR METASTATIC BREAST CANCER

Ref-No: TA-P-1157

BACKGROUND

The technology describes two serum/plasma markers, in combination or alone, for stage discrimination and prediction of survival as well as treatment response in breast cancer patients. Test statistics show that these markers perform better than established ones like the number of circulating tumor cells (CTCs).

SOLUTION

- Discrimination between metastatic and non-metastatic breast cancer
  AUC of ROC curve = 0.85.
- Marker for diagnostic, prognostic and treatment monitoring of metastatic breast cancer.

Deutsches Krebsforschungszentrum DKFZ

Dr. Frieder Kern
+49-6221-42-2952
f.kern@dkfz.de
www.dkfz.de

DEVELOPMENT STATUS

Pre clinical

CATEGORIES

//Research tools //Medicine and pharmaceutics //Diagnostics
ROC analysis of plasma HA in combination with S100P level changes indicating treatment outcome of metastatic breast cancer patients.

ADVANTAGES

- More accurate prediction of progression-free and overall survival than presence of CTCs.
- More accurate prediction of treatment response than presence of CTCs.

SCOPE OF APPLICATION

Common ELISA technology has been used for detection of hyaluronic acid and S100P in plasma of breast cancer patients.

PUBLICATIONS & LINKS